Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.

"CONFLICT OF INTEREST Grazyna A. Stanczuk: Employer has received donation of HPV diagnostic tests from Roche. Grazyna A. Stanczuk received travel support and honoraria for speaking from Roche and Abbott. While Roche donated Cobas 4800 PCR‐based DNA test kits and consumables for the baseline study, Roche had no role in data analysis and holds no editorial rights over project data, databases or manuscripts. Kate Cuschieri: Employer has received research funding or gratis consumables to support research from the following commercial entities in the last 3 years: Cepheid, Euroimmun, GeneFirst, SelfScreen, Hiantis, Seegene, Roche, Abbott and Hologic. Marc Arbyn was supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network (Grant No. 847845) and the European Society for Gynaecologic Oncology; Sciensano the employer or Marc Arbyn received funding in the framework of Valgent and VALHUDES, which are two researcher induced protocols for evaluation of HPV tests on cervical and vaginal samples respectively (see Arbyn et J Clin Virol 2016 & 2018). Marc Arbyn did not receive any financial or material benefit from these projects. All other authors have nothing to declare."

"Funding information The PaVDaG study was sponsored by NHS Dumfries and Galloway and supported by funding from the Chief Scientist Office of the Scottish Government."